相关实验视频
Updated: Jul 17, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.1K
2024年更新:大B细胞淋巴瘤风险分层和管理方面的进展
Montreh Tavakkoli1, Stefan K Barta1
1Department of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
American journal of hematology
|August 30, 2023
概括
扩散性大B细胞淋巴瘤 (DLBCL) 管理正在随着分子洞察力和AI而发展. 像CAR T细胞疗法这样的新疗法为耐火性疾病提供了更好的结果,提高了风险评估和监测.
科学领域:
- 血液学和瘤学研究
- 分子生物学分子生物学
- 人工智能在医学中的应用
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种复杂而异质的淋巴状恶性瘤.
- 在DLBCL的临床结果有很大的差异,需要改进风险分层和管理策略.
- 了解分子异质性的进展对于个性化治疗方法至关重要.
研究的目的:
- 审查目前扩散型大B细胞淋巴瘤 (DLBCL) 的分类和管理.
- 突出最近的治疗进展和DLBCL治疗中的新兴技术.
- 强调分子分析,人工智能和ctDNA在风险评估和疾病监测中的作用.
主要方法:
- 关于DLBCL分类和治疗的最新研究的综合文献综述.
- 对前线疗法的分析,包括R-CHOP和Pola-R-CHP.
- 对复发性/耐药性疾病的先进疗法,如仿真抗原受体 (CAR) T 细胞疗法和自身干细胞移植的评估.
主要成果:
- 化学抗原受体 (CAR) T细胞疗法已被确立为初级耐火DLBCL的标准护理.
- CAR T细胞疗法和自身干细胞移植都是复发性和耐火性DLBCL的关键选择.
- 人工智能和循环瘤DNA (ctDNA) 分析显示,增强风险分层和监测具有前景.
结论:
- 由于分子发现和创新的治疗策略,DLBCL的治疗正在迅速发展.
- 个性化治疗方法对于优化患者的治疗结果变得越来越重要.
- 未来的方向包括整合AI和ctDNA,以便在DLBCL中更精确地管理疾病.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K